A growing body of evidence demonstrated that RUNX2 is aberrantly expressed in several human cancers including pancreatic,23 thyroid,24 breast,25,26 prostate,27 lung,28 colon,29 ovarian cancers30 and osteosarcoma.31,32 Consistent with these observations, it has been shown that RUNX2 has an ability to transactivate genes implicated in cancer cell migration and invasion.33–38 Indeed, Tandon et al.39 revealed that knockdown of RUNX2 in invasive breast cancer cells promotes cell death in response to glucose- and growth factor-deprivation. Here, RUNX2 is linked to osteosarcoma.